source
- Argenx to buy Forte Biosciences for up to $2.2 billion, adding experimental CD122 drug FB102Argenx announced it will acquire Forte Biosciences in a transaction valued at up to $2.2 billion. The purchase price is set at $77 per Forte share, roughly a 41% premium to the previous closing pr…
- Global HIV funding drops 18%, raising fears of epidemic resurgenceA new UNAIDS report warns that the world could see a rebound of HIV infections after donor financing fell sharply last year. Government contributions dropped by more than $1.5 billion to $7.3 bill…